Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C

Clinical Transplantation

Volumn 19, Issue 1, 2005, Pages 83-89

  Kamar, Nassim ^a   Borde, Jean Sébastien ^a   Sandres Saune, Karine ^b   Suc, Bertrand ^c   Barange, Karl ^b   Cointault, Olivier ^a   Lavayssière, Laurence ^a   Durand, Dominique ^a   Izopet, Jacques ^b   Rostaing, Lionel ^a,c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b CHU PURPAN   (France)

^c CHU RANGUEIL   (France)

Author keywords

Anti CD25 monoclonal antibodies; Efficacy; Hepatitis C virus; Orthotopic liver transplantation; Rabbit antithymocyte globulins; Safety

Indexed keywords

BASILIXIMAB; COTRIMOXAZOLE; CYCLOSPORIN A; DACLIZUMAB; DIPHENHYDRAMINE; GANCICLOVIR; INSULIN; LIVER ENZYME; METHYLPREDNISOLONE; OKT 3; PARACETAMOL; PEGINTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; TACROLIMUS; THYMOCYTE ANTIBODY; THYMOGLOBULINS; UNCLASSIFIED DRUG; VALACICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTHRALGIA; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE RESISTANCE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS C; HUMAN; HYPOCOMPLEMENTEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER FAILURE; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MALE; MYCOSIS; NEUROTOXICITY; PNEUMOCYSTIS PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE RISK; SERUM SICKNESS; THROMBOCYTOPENIA;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; COHORT STUDIES; FEMALE; GRAFT SURVIVAL; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; RABBITS; RECEPTORS, INTERLEUKIN-2; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 13644256417     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2004.00302.x     Document Type: Article

References (25)

1. Fukumoto T, Berg T, Ku Y et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turn over of serum virons. Hepatology 1996: 24: 1351.
2. Neumann U, Berg T, Bahra M et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004: 77: 226.
3. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003: 9: S28.
4. Calmus Y, Scheele JK, Gonzalez-Pinto I et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002: 8: 123.
5. Neuhaus P, Clavien PA, Kittur D et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002: 8: 132.
6. Nelson DR, Soldevila-Pico C, Reed A et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001: 7: 1064.
7. Rosen HR, Shackleton CR, Higa L et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997: 92: 1453.
8. Eason JD, Loss GE, Blazek J, Nair S, Mason AL. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transpl 2001: 7: 693.
9. Fasola C, Klintmalm G, Group CHTS. Multicenter randomized hepatitis C (HCV) three trial post liver transplantation (OLT): a preliminary report. Am J Transplant 2004: 4 (Suppl. 8): 410 A924.
10. Netto G, Group thCTT. Histologic evaluatio of hepatitis C recurrence and acute cellular rejection following OLTX: a preliminary report on the hepatitis C three trial. Am J Transplant 2004: 4 (Suppl. 8): 357 A733.
11. Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002: 36: 202.
12. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003: 9: S63.
13. Gane EJ, Naoumov NV, Qian KP et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996: 110: 167.
14. Starzl TE. Experience in hepatic transplantation. In: Starzl TE, Putman CW, eds. Immunosuppression in man. Philadelphia: Saunders, 1965.
15. Cisneros Alonso C, Diaz Castellanos MA, Montero Castillo A et al. Antilymphocytic sera versus azathioprine, combined with cyclosporin and steroids, in liver transplant. Comparison of the results at the intensive care unit and 2 years' follow-up. Rev Clin Esp 1990: 186: 68.
16. Langrehr JM, Klupp J, Junge G et al. Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial. Transplant Proc 2001: 33: 2330.
17. Rafecas A, Llado L, Albiol MT et al. Immunosuppression with calcineurin inhibitors and polyclonal antibodies in liver transplantation. Transplant Proc 2002: 34: 107.
18. Tector AJ, Fridell JA, Mangus RS et al. Promising early results with immunosuppression using rabbit antithymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl 2004: 10: 404.
19. Wall WJ. Use of antilymphocyte induction therapy in liver transplantation. Liver Transpl Surg 1999: 5(Suppl. 1): S64.
20. Llado L, Figueras J, Ramos E et al. Prospective evaluation of a quadruple therapy based on tacrolimus after liver transplantation. Transplant Proc 2002: 34: 108.
21. Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE. Jr. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003: 75: 1396.
22. Missale G, Bertoni R, Lamonaca V et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996: 98: 706.
23. Gerlach JT, Diepolder HM, Jung MC et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999: 117: 933.
24. Nelson DR, Marousis CG, Davis GL et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997: 158: 1473.
25. Rosen HR, Miner C, Sasaki AW et al. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology 2002: 35: 190.